Skip to main content

Table 5 Change in accompanying symptoms between TSC and placebo groups in the full analysis set (FAS)

From: Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial

Accompanying symptomsTSC (N = 750)Placebo (N = 250)P values
Nausea, mean ± SD, no.4 weeks2.50 ± 1.432.66 ± 1.470.1194
8 weeks1.89 ± 1.322.38 ± 1.47< 0.0001
12 weeks1.34 ± 1.192.18 ± 1.49< 0.0001
16 weeks1.06 ± 1.102.21 ± 1.59< 0.0001
Vomiting, mean ± SD, no.4 weeks0.77 ± 1.220.93 ± 1.330.0523
8 weeks0.47 ± 0.970.83 ± 1.340.0002
12 weeks0.31 ± 0.780.71 ± 1.29< 0.0001
16 weeks0.21 ± 0.700.79 ± 1.45< 0.0001
Photophobia, mean ± SD, no.4 weeks0.98 ± 1.401.25 ± 1.580.0338
8 weeks0.69 ± 1.170.97 ± 1.390.0029
12 weeks0.48 ± 0.990.91 ± 1.39< 0.0001
16 weeks0.42 ± 0.880.95 ± 1.51< 0.0001
Phonophobia, mean ± SD, no.4 weeks0.67 ± 1.210.76 ± 1.310.3528
8 weeks0.44 ± 0.960.63 ± 1.230.0278
12 weeks0.34 ± 0.870.57 ± 1.190.0023
16 weeks0.33 ± 0.830.61 ± 1.190.0002
  1. no. number, SD Standard deviation